You just read:

Menlo Therapeutics Signs Exclusive License Agreement with Japan Tobacco and Torii Pharmaceuticals for Development and Commercialization of NK-1 receptor antagonist in Japan

News provided by

Menlo Therapeutics Inc.

Aug 10, 2016, 13:00 ET